Streetbeat News

SMMT

Summit Therapeutics Inc.

https://www.summittxinc.com

Industry

Biotechnology

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Open

19.45

Mkt cap

13B

Volume

2.1M

High

19.45

P/E Ratio

-79.61

52-wk high

33.89

Low

18.23

Div yield

N/A

52-wk low

1.88

U.S. stocks traded lower with the Nasdaq Composite down over 200 points. Consumer staples shares rose by 1.2%, while information technology shares fell by 1.8%. The Conference Board's Leading Economic Index fell 0.4% for January. Monopar Therapeutics, Biofrontera, and TRxADE HEALTH saw significant stock increases due to positive company news. Conversely, RAPT Therapeutics, Summit Therapeutics, and Fluor Corporation experienced notable declines following negative developments.

Portfolio Pulse from Avi Kapoor

February 20, 2024 | 7:33 pm

Fluor Corporation's shares fell by 7.7% following its Q4 results, with earnings beating estimates but sales missing expectations. Other stocks moved significantly in Tuesday's session, with notable gainers including TRxADE HEALTH, AgriFORCE Growing Systems, and Monopar Therapeutics, among others, due to various positive announcements. Losers included RAPT Therapeutics, MicroCloud Hologram, and Summit Therapeutics, primarily due to negative news or disappointing results.

Portfolio Pulse from Avi Kapoor

February 20, 2024 | 6:21 pm

In Tuesday's intraday session, several healthcare stocks experienced significant movements. Monopar Therapeutics led the gainers with a 138.8% increase, while RAPT Therapeutics saw the largest decline at 66.2%. Other notable movers include Trxade Health, Biofrontera, Iovance Biotherapeutics, and SeaStar Medical Holding among the gainers, and Summit Therapeutics, Better Therapeutics, Universe Pharmaceuticals, Sientra, and Tenaya Therapeutics among the losers.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 5:31 pm

U.S. stocks traded lower with the Dow, Nasdaq, and S&P 500 all experiencing declines. The Conference Board's Leading Economic Index fell 0.4% for January. Monopar Therapeutics, AgriFORCE Growing Systems, and TRxADE HEALTH saw significant stock price increases due to positive company developments. Conversely, RAPT Therapeutics, Summit Therapeutics, and Fluor Corporation faced notable declines following negative news or earnings reports.

Portfolio Pulse from Avi Kapoor

February 20, 2024 | 5:09 pm

Summit Therapeutics shares are trading lower following the announcement of their Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 4:38 pm

Summit Therapeutics announced that it now has enough cash to operate into the first quarter of 2025, indicating a stronger financial position.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:51 pm

Summit Therapeutics reported a Q4 EPS loss of $(0.05), marking a 28.57% improvement from the $(0.07) per share loss reported in the same quarter last year.

Portfolio Pulse from totan@benzinga.com

February 20, 2024 | 12:07 pm

Earnings reports for various companies are scheduled for February 20, 2024, with a mix of projected earnings and losses across different sectors. Notable companies include Walmart, Home Depot, Medtronic, and Barclays, among others, with expectations ranging from significant profits to losses per share.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 11:52 am

BlackBerry Limited's stock (NYSE:BB) fell by over 17% after announcing a proposed private offering of $160 million in convertible senior notes. Other stocks experienced significant movement in Wednesday's mid-day session, with notable gainers including Getaround, Inc. (NYSE:GETR), Evaxion Biotech A/S (NASDAQ:EVAX), and SciSparc Ltd. (NASDAQ:SPRC), among others. Losers included Richtech Robotics Inc. (NASDAQ:RR), Rail Vision Ltd. (NASDAQ:RVSN), and Gamer Pakistan Inc. (NASDAQ:GPAK).

Portfolio Pulse from Avi Kapoor

January 24, 2024 | 6:05 pm

U.S. stock futures are down, with Dow Jones futures dropping about 100 points. Hewlett Packard Enterprise (HPE) shares fell 8.5% in pre-market trading amid reports of a potential acquisition of Juniper Networks (JNPR) for approximately $13 billion. Other stocks experiencing pre-market losses include Grifols (GRFS), CyberArk Software (CYBR), Summit Therapeutics (SMMT), Nkarta (NKTX), Hologic (HOLX), Microchip Technology (MCHP), Prothena Corporation (PRTA), and Heron Therapeutics (HRTX).

Portfolio Pulse from Avi Kapoor

January 09, 2024 | 11:36 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.